SEC Filings
Arcus Biosciences Closes Stock Sale Of 16,428,572 Shares, Underwriters Take Full Extra Option
The cancer-drug developer netted about $269.7 million after the underwriters exercised their option in full when the deal closed Friday.
RCUS
Arcus Biosciences (RCUS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Arcus Biosciences Prices $250 Million Stock Sale At $17.50 A Share, 8.4% Below Wednesday's Close
The cancer drug developer is selling 14,285,715 new shares, 10.1% of the count outstanding after the deal, with proceeds aimed at its kidney-cancer drug.
SEC Filings
Arcus Biosciences Puts Quarter-End Cash At About $694.0 Million, Unaudited
The preliminary figure covers cash and securities as of September 30 and has not been reviewed by the company's outside auditor.
SEC Filings
Arcus Kidney Cancer Drug Casdatifan Hits 14.5-Month Median PFS With Cabozantinib In Second Line
Arcus reported 44% confirmed responses in 43 second-line patients, plus first-line and late-line data, in an 8-K.